Currently, TATTON studies have shown the feasibility of combining osimertinib 80 mg with savolitinib at identified tolerable,[12] and on-treatment ctDNA dynamics can predict clinical outcomes and may provide an opportunity to inform earlier decision-making.[13] Meanwhile, the FLOWERS study also showed better perspectives on the efficacy and safety of EGFR-TKI plus MET-TKI combination therapy in patients with de novo MET-amplified/over-expressed, EGFR-mutant positive, treatment naïve, advanced NSCLC and offer a meaningful guidance in clinical practice. The gene discussed is MET; the disease is non-small cell lung carcinoma.